The UK Health Security Agency designated a Delta coronavirus subvariant called AY.4.2 as a “Variant Under Investigation,” saying there was some evidence that it could be more transmissible than Delta.

Americans can choose a Covid-19 booster shot that is different from their original inoculation but the recommendation is to stick with the vaccine they got first if available, White House chief medical adviser Dr. Anthony Fauci said on Oct. 22.

Pfizer, Moderna, and AstraZeneca have been running “dress rehearsals” by adapting their current formulations of Covid-19 vaccines to match present known SARS-CoV-2 variants.

British health authorities, as well as global experts, are closely watching a subtype of the Delta variant that appears to be rising in the UK.

Japan’s Shionogi & Co. Ltd. said on Oct. 20 the company started a Phase II/III clinical trial for the drugmaker’s Covid-19 vaccine candidate.

Biogen Inc. is pinning hopes on a decision on U.S. government coverage of the company’s Alzheimer’s disease drug during 2022 to help drive up Aduhelm’s usage, after a big miss on third-quarter 2021 sales of the much-awaited treatment.

U.S. Supreme Court Justice Stephen Breyer on Oct. 19 turned away a religious challenge to a requirement that healthcare workers in Maine be vaccinated against Covid-19, the latest such bid rejected by the nation’s top judicial body.

Valneva SE on Oct. 18 said the company’s experimental Covid-19 vaccine demonstrated efficacy “at least as good, if not better” than AstraZeneca’s shot in a late-stage trial comparing the two, with significantly fewer adverse side effects.

The Greater Than One (GTO) Group announced the introduction of a new operating model to better serve clients outside the United States. Referred to as OUS (Outside United States) On-Demand, the new model will bring the same level of service innovation and value creation abroad as US-based clients experience today.

Four leading pharmaceutical companies partnered with Amazon Web Services and Israel Biotech Fund to launch AION Labs, an innovative space that will allow drug developers to harness artificial intelligence technologies and computational science to solve therapeutic challenges.